BRIEF published on 11/26/2025 at 00:51, 10 months 27 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 10 months 27 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 10 months 28 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 10 months 28 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 1 year 2 months ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 1 year 2 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 1 year 2 months ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 1 year 2 months ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 1 year 3 months ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 1 year 3 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 10/23/2026 at 02:20, 9 hours 48 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 12 hours 38 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 13 hours 38 minutes ago Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update
Published on 10/22/2026 at 16:00, 20 hours 8 minutes ago Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 21 hours 38 minutes ago Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/23/2026 at 11:45, 23 minutes ago Original-Research: Grand City Properties SA (von First Berlin Equity Research GmbH): Kaufen
Published on 10/23/2026 at 11:30, 38 minutes ago Bulgarian Financial Supervision Commission completes preliminary review of the voluntary public takeover offer for Shelly Group SE
Published on 10/23/2026 at 11:30, 38 minutes ago Acceptance period of Sazerac’s voluntary public takeover offer for Berentzen-Gruppe Aktiengesellschaft commences
Published on 10/23/2026 at 11:00, 1 hour 8 minutes ago Annual General Meeting Approves Contribution: Innok Robotics on Course for the Public Capital Market
Published on 10/22/2026 at 18:00, 18 hours 8 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 18 hours 8 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 18 hours 8 minutes ago H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 18 hours 21 minutes ago Aéroports de Paris SA - 2026 9-month revenue
